Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Structure and Function of Platelets01:18

Structure and Function of Platelets

7.3K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
7.3K
Introduction to Hemostasis01:05

Introduction to Hemostasis

14.5K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
14.5K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

6.3K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.3K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

11.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.1K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

6.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.

ESMO open·2025
Same author

A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancer.

British journal of cancer·2007
Same author

In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic.

Thrombosis research·2001
Same author

Characterization of the immune response to factor VIII using hemophilia A* mice.

Haematologica·2001

Related Experiment Video

Updated: May 6, 2026

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

10.9K

von Willebrand factor and platelet function.

R Moroose, L W Hoyer

    Annual Review of Medicine
    |January 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Platelet-von Willebrand factor (VWF) interactions and vascular endothelium are key in hemostasis. Advances in assessment methods have improved recognition of platelet-VWF disorders and their treatments.

    More Related Videos

    Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
    08:30

    Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

    Published on: August 14, 2017

    10.9K
    Microfluidics in Assessing Platelet Function
    06:47

    Microfluidics in Assessing Platelet Function

    Published on: November 8, 2024

    1.7K

    Related Experiment Videos

    Last Updated: May 6, 2026

    Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
    11:42

    Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

    Published on: July 10, 2017

    10.9K
    Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
    08:30

    Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

    Published on: August 14, 2017

    10.9K
    Microfluidics in Assessing Platelet Function
    06:47

    Microfluidics in Assessing Platelet Function

    Published on: November 8, 2024

    1.7K

    Area of Science:

    • Hematology
    • Vascular Biology
    • Platelet Biology

    Background:

    • The intricate relationship between platelets, von Willebrand factor (VWF), and the vascular endothelium is crucial for hemostasis.
    • Recent advancements in assessment methodologies have enhanced our understanding of these interactions.
    • This has led to improved identification of clinical conditions stemming from impaired platelet-VWF interactions.

    Purpose of the Study:

    • To review the complex interactions of platelets, VWF, and vascular endothelium.
    • To highlight the increased recognition of diseases linked to defects in platelet-VWF interaction.
    • To discuss emerging therapeutic strategies for VWF functional disorders.

    Main Methods:

    • Literature review of studies focusing on platelet-VWF-endothelium interactions.
    • Analysis of recent advancements in diagnostic and assessment techniques for VWF function.
    • Synthesis of current therapeutic approaches for VWF-related bleeding disorders.

    Main Results:

    • Enhanced understanding of the molecular mechanisms governing platelet adhesion and aggregation.
    • Improved diagnostic capabilities for identifying subtle defects in VWF function.
    • Development of novel therapeutic options, including VWF replacement and alternative hemostatic agents.

    Conclusions:

    • The study underscores the critical role of platelet-VWF interactions in vascular hemostasis.
    • Improved diagnostic tools have facilitated earlier and more accurate disease recognition.
    • A growing array of therapeutic interventions offers better management for patients with VWF disorders.